RESUMEN
ObjectiveTo explore the possible mechanism of Changweiqing (肠胃清) in the treatment of colorectal cancer. MethodsHCT 116 cancer cells were used to prepare intestinal cancer cells with silenced polypyrimidine region binding protein 3 (PTBP3) gene and stably transfected cells with overexpressed PTBP3 gene. Stably transfected cells with silenced PTBP3, stably transfected cells with overexpressed PTBP3 and untransfected cancer cells were injected into the armpit of 72 nude mice to construct three different subcutaneous transplanted tumor models of colorectal cancer cells, including the silenced model, the overexpressed model and the control model, with 24 mice per model. Mice of each transplanted tumor modelwere randomly divided into Changweiqing (CWQ) group, oxaliplatin (OXA) group and normal saline (NS) group, with 8 mice in each group. The CWQ groups were given intragastric administration of 35.9625 g/kg of Changweiqing oral liquid and were intraperitoneally injected with 0.2ml of normal saline; the NS groups were given 0.5ml of normal saline by gavage, and intraperitoneal injection of 0.2ml of normal saline; the OXA groups were intraperitoneally injected with 5 mg/kg (0.2 ml) of oxaliplatin and given 0.5ml of normal saline by gavage. Each group was given intragastric administration once a day and intraperitoneal injection three times a week. After 31 days, the weight of subcutaneous tumors in each group was measured, and the tumor inhibition rate of the groups in each model were measured. Immunohistochemistry and other methods were used to detect the expression level of cell proliferation cell nuclear antigen Ki67 and apoptosis index. Real-time PCR and Western Blot were used to detect mRNA and protein expressions of PTBP3, signal transducer and activator of transcription 3 (STAT3) splicing isoform α (STAT3α), STAT3 splicing isoform β (STAT3β), B-cell lymphoma/leukemia-2 (Bcl-2) splicing isoform α (Bcl-2α), and Bcl-2 splicing isoform β (Bcl-2β) in subcutaneous tumor cells in each group. ResultsFor all three transplanted tumor models, the weight of the subcutaneous tumors and Ki67 expression level of subcutaneous tumor tissue in all CWQ groups and OXA groups were lower than those of the corresponding NS groups, while the apoptosis level were higher (P<0.05 or P<0.01). The mRNA and protein expressions of PTBP3, STAT3α, and Bcl-2α in the subcutaneous tumor tissues of the silenced model CWQ group and the overexpressed model CWQ group were lower than those of the corresponding NS groups, while the mRNA and protein expression levels of STAT3β and Bcl-2β were higher (P<0.05 or P<0.01). All there groups of silenced model had lower subcutaneous tumor weight, Ki67 expression level, and mRNA and protein expression levels of PTBP3, STAT3α, and Bcl-2α in subcutaneous tumor tissue, as well as higher apoptosis level and mRNA and protein expression levels of STAT3β and Bcl-2β than those in all groups of control model; all groups of overexpressed model had higher subcutaneous tumor weight, Ki67 expression level, and mRNA and protein expression levels of PTBP3, STAT3α, and Bcl-2α , while lower apoptosis level and mRNA and protein expression levels of STAT3β and Bcl-2β than those in all control model groups (P<0.05 or P<0.01). In the control model, compared with the NS group, The tumor inhibition rate of all OXA groups was higher than that of corresponding CWQ groups, respectively. Compared to that of each control model group, the tumor inhibition rate was positive value of each silenced model group, and negative value of each overexpressed model group. ConclusionPTBP3 can promote the proliferation and inhibit apoptosis of intestinal cancer cells, upregulate the expression of STAT3α and Bcl-2α, and downregulate the expression of STAT3β and Bcl-2β in intestinal cancer cells. The meachnism of action of Changweiqing in the treatment of colorectal cancer maybe related to the inhibition of PTBP3, and regulation of the expression of STAT3α, STAT3β, Bcl-2α, and Bcl-2β.
RESUMEN
The anti-tumor effect of anti-PD-1 antibody has long been shown to be strongly related to the tumor immune microenvironment (TIME). This study aimed to mechanistically assess whether Chang Wei Qing (CWQ) Decoction can enhance the anti-tumor effect of PD-1 inhibitor therapy. PD-1 inhibitor therapy showed the significant anti-tumor effect in patients with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC), rather than those with mismatch repair-proficient/microsatellite stable (pMMR/MSS) CRC. Hence, immunofluorescence double-label staining was utilized to explore the difference in the TIME between dMMR/MSI-H and pMMR/MSS CRC patients. Flow cytometry was used to analyze T-lymphocytes in tumors from mice. Western blot was used to measure the expression of PD-L1 protein in mouse tumors. The intestinal mucosal barrier of mice was evaluated by hematoxylin-eosin staining and immunohistochemistry. 16S rRNA-gene sequencing was used to examine the structure of the gut microbiota in mice. Subsequently, Spearmanapos;s correlation analysis was used to analyze the relationship between the gut microbiota and tumor-infiltrating T-lymphocytes. The results showed that dMMR/MSI-H CRC patients had more CD8+T cells and higher expression of PD-1 and PD-L1 proteins. In vivo, CWQ enhanced the anti-tumor effect of anti-PD-1 antibody and increased the infiltration of CD8+ and PD-1+CD8+ T cells in tumors. Additionally, the combination of CWQ with anti-PD-1 antibody resulted in lower inflammation in the intestinal mucosa than that induced by anti-PD-1 antibody alone. CWQ and anti-PD-1 antibody co-treatment upregulated PD-L1 protein and reduced the abundance of Bacteroides in the gut microbiota but increased the abundance of Akkermansia,Firmicutes, andActinobacteria. Additionally, the proportion of infiltrated CD8+PD-1+, CD8+, and CD3+ T cells were found to be positively correlated with the abundance of Akkermansia. Accordingly, CWQ may modulate the TIME by modifying the gut microbiota and consequently enhance the anti-tumor effect of PD-1 inhibitor therapy.
Asunto(s)
Animales , Ratones , Inhibidores de Puntos de Control Inmunológico/uso terapéutico , Microbioma Gastrointestinal , Linfocitos T CD8-positivos , Antígeno B7-H1 , ARN Ribosómico 16S , Neoplasias Colorrectales/metabolismo , Neoplasias del Colon , Microambiente TumoralRESUMEN
OBJECTIVE@#To explore the therapeutic mechanism of Liushen Wan (LSW) against colitis-associated colorectal cancer (CAC) by network pharmacology.@*METHODS@#TCMSP, BATMAN-TCM, CNKI, PubMed, Genecards, OMIM, and TTD databases were used to obtain the related targets of LSW and CAC. The common targets of LSW and CAC were obtained using Venny online website. The PPI network was constructed using Cytoscape 3.8.2 to screen the core targets of LSW in the treatment of CAC. GO and KEGG enrichment analysis were conducted using DAVID database. The therapeutic effect of LSW on CAC was evaluated in a C57BL/6J mouse model of AOM/DSS-induced CAC by observing the changes in body weight, disease activity index, colon length, and size and number of the tumor. HE staining and RT-qPCR were used to analyze the effect of LSW on inflammatory mediators. Immunohistochemistry and TUNEL staining were used to evaluate the effect of LSW on the proliferation and apoptosis of AOM/DSS-treated colon tumor cells. Immunohistochemistry and Western blotting were used to detect the effects of LSW on the expression of TLR4 proteins in CAC mice.@*RESULTS@#Network pharmacology analysis identified 69 common targets of LSW and CAC, and 33 hub targets were screened in the PPI network. KEGG pathway enrichment analysis suggested that the effect of LSW on CAC was mediated by the Toll-like receptor signaling pathway. In the mouse model of AOM/DSS-induced CAC, LSW significantly inhibited colitis-associated tumorigenesis, reduced tumor number and tumor load (P < 0.05), obviously improved histopathological changes in the colon, downregulated the mRNA levels of proinflammatory cytokines, and inhibited the proliferation (P < 0.01) and promoted apoptosis of colon tumor cells (P < 0.001). LSW also significantly decreased TLR4 protein expression in the colon tissue (P < 0.05).@*CONCLUSION@#LSW can inhibit CAC in mice possibly by regulating the expression of TLR4 to reduce intestinal inflammation, inhibit colon tumor cell proliferation and promote their apoptosis.
Asunto(s)
Ratones , Animales , Receptor Toll-Like 4 , Neoplasias Asociadas a Colitis , Farmacología en Red , Ratones Endogámicos C57BL , Neoplasias del Colon/patologíaRESUMEN
Epithelial-mesenchymal transition (EMT) is a differentiation process of epithelial cells into mesenchymals,which is widespread in the invasion and metastasis of malignant tumor.Studies show that EMT is influenced by a variety of factors such as cytokines,signaling pathways and transcription factors.Studies also show that intracellular and extracellular signal transmission could induce EMT.Signal transduction is a process which involves ligand-receptor binding in the extracellular,going into the cell and activating different nuclear transduction factor through intracellular signal transduction pathway.
RESUMEN
Objective To analyze the drug using regularity in treating breast cancer in spring of professor Lu Ming. Methods Prescriptions that treated breast cancer in 2013 spring of professor Lu Ming were collected, and then metrology analysis was used to study the frequency, property, flavor and meridian attribution of herbal medicine in these prescriptions, and analyze their basic medication features. Results Among the collected 111 prescriptions of professor Lu Ming for treatment of breast cancer, the most often used prescription was sedatives and tranquilizers and nourishing yin;commonly used medications were Lanceleaf lily bulb, cortex albiziae, radix astragali, radix paeoniae alba and so on. The herbal medicine used included five kinds of properties, and the two most common ones were warm and plain. There were six different flavors, among which sweet and bitter were the two most common ones. Nine meridian attributions were identified, among which liver meridian and spleen meridian were the two most common ones. Conclusion Clinical treatment of breast cancer should be based on sweet-warm nourishing herbal medicine, while paying attention to tranquilizing and sedating the mind. Symptoms should be treated by using clearing heat and promoting diuresis. In addition, it should be noted that the spring medication should conform the warmth of spring qi.